Symbiosis Pharmaceutical Services Limited

www.symbiosis-pharma.com

Symbiosis Pharmaceutical Services Ltd, licensed by the MHRA, is a world-class fill/finish business that specializes in the GMP manufacture of sterile pharmaceuticals for clinical trials.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

AKILI ANNOUNCES PUBLIC COMPANY BOARD OF DIRECTOR NOMINEES

Akili Interactive | July 11, 2022

news image

Akili Interactive a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, announced the nominees for its future board of directors, effective upon the closing of Akili’s business combination with Social Capital Suvretta Holdings Corp. I subject to customary closing conditions. Shares of the new public company’s common stock are expected to trade on Nasdaq under the symbol “AKLI.” Akili’...

Read More

Industrial Impact

QUANTUM GENOMICS SIGNS AN EXCLUSIVE LICENSE AND PRODUCTION AGREEMENT WITH GULF PHARMACEUTICALS INDUSTRIES JULPHAR

Quantum Genomics | December 06, 2021

news image

Quantum Genomics, a biopharmaceutical company specializing in the development of first-in-class drugs directly targeting the brain to treat complex/resistant hypertension, has announced the signing of an exclusive license and production agreement with Julphar to market and produce firibastat in the Middle East, all African countries, Commonwealth of Independent States and Turkey. A pharmaceutical company based in the United Arab Emirates and leader in the MENA region, Julphar will...

Read More

Medical

MERCK ENTERS INTO SUPPLY AGREEMENT WITH U.S. GOVERNMENT TO MANUFACTURE AND INITIAL DISTRIBUTION OF INVESTIGATIONAL BIOLOGICAL THERAPEUTIC

Merck | December 28, 2020

news image

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today declared it has gone into a agreement with the United States Government to help the turn of events, assembling and introductory dispersion of an investigational biological therapeutic (CD24Fc, to be named MK-7110) upon endorsement or Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Merck acquired MK-7110 through the securing of OncoImmune, a privately held, clinical-stage biopharmaceuti...

Read More

Medical

CAPRICOR THERAPEUTICS ANNOUNCES COLLABORATION WITH THE NATIONAL INSTITUTES OF HEALTH FOR CLINICAL TRIAL OF NOVEL EXOSOME-BASED MULTIVALENT VACCINE

Capricor Therapeutics | January 24, 2024

news image

Capricor Therapeutics a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, today announced that Capricor’s proprietary StealthX™ exosome-based multivalent vaccine (StealthX™ vaccine) for the prevention of SARS-CoV-2 has been selected to be part of Project NextGen, an initiative by the U.S. Department of Health and Human Services to advance a pipeline of new, innovative vaccines providing b...

Read More
news image

Industrial Impact

AKILI ANNOUNCES PUBLIC COMPANY BOARD OF DIRECTOR NOMINEES

Akili Interactive | July 11, 2022

Akili Interactive a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, announced the nominees for its future board of directors, effective upon the closing of Akili’s business combination with Social Capital Suvretta Holdings Corp. I subject to customary closing conditions. Shares of the new public company’s common stock are expected to trade on Nasdaq under the symbol “AKLI.” Akili’...

Read More
news image

Industrial Impact

QUANTUM GENOMICS SIGNS AN EXCLUSIVE LICENSE AND PRODUCTION AGREEMENT WITH GULF PHARMACEUTICALS INDUSTRIES JULPHAR

Quantum Genomics | December 06, 2021

Quantum Genomics, a biopharmaceutical company specializing in the development of first-in-class drugs directly targeting the brain to treat complex/resistant hypertension, has announced the signing of an exclusive license and production agreement with Julphar to market and produce firibastat in the Middle East, all African countries, Commonwealth of Independent States and Turkey. A pharmaceutical company based in the United Arab Emirates and leader in the MENA region, Julphar will...

Read More
news image

Medical

MERCK ENTERS INTO SUPPLY AGREEMENT WITH U.S. GOVERNMENT TO MANUFACTURE AND INITIAL DISTRIBUTION OF INVESTIGATIONAL BIOLOGICAL THERAPEUTIC

Merck | December 28, 2020

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today declared it has gone into a agreement with the United States Government to help the turn of events, assembling and introductory dispersion of an investigational biological therapeutic (CD24Fc, to be named MK-7110) upon endorsement or Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Merck acquired MK-7110 through the securing of OncoImmune, a privately held, clinical-stage biopharmaceuti...

Read More
news image

Medical

CAPRICOR THERAPEUTICS ANNOUNCES COLLABORATION WITH THE NATIONAL INSTITUTES OF HEALTH FOR CLINICAL TRIAL OF NOVEL EXOSOME-BASED MULTIVALENT VACCINE

Capricor Therapeutics | January 24, 2024

Capricor Therapeutics a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, today announced that Capricor’s proprietary StealthX™ exosome-based multivalent vaccine (StealthX™ vaccine) for the prevention of SARS-CoV-2 has been selected to be part of Project NextGen, an initiative by the U.S. Department of Health and Human Services to advance a pipeline of new, innovative vaccines providing b...

Read More

Resources

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us